The Affordable Drug Manufacturing Act of 2023 would establish a new Office of Drug Manufacturing within the Department of Health and Human Services to produce generic and biosimilar medications directly to compete with private manufacturers and lower drug prices. The office would be headed by a presidential appointee and would prioritize manufacturing at least 15 drugs within one year and 25 drugs within three years, with mandatory focus on insulin, asthma and COPD inhalers, naloxone, epinephrine auto-injectors, and antibiotics. The office would set "fair prices" based on factors like manufacturing costs, patient access, and market competition, then sell drugs to wholesalers and direct purchasers while making all pricing publicly available. The bill allows the office to contract with nonprofit entities and public partners for manufacturing and to acquire rights to produce active pharmaceutical ingredients when they are in short supply or produced by only one facility. The legislation does not specify funding levels but authorizes whatever appropriations are necessary to operate the program.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.